Increasing levels of leukocyte-derived inflammatory mediators in plasma and cAMP in platelets during follow-up after acute cerebral ischemia

Cerebrovascular Diseases

Volumn 8, Issue 6, 1998, Pages 310-317

  Anwaar, I ^a   Gottsater A ^a   Ohhson, K ^a   Mattiasson F Lindgarde, I ^a  

^a LUND UNIVERSITY   (Sweden)

Author keywords

cAMP; Cerebral ischemia; Cytokines; Stroke

Indexed keywords

CYCLIC AMP; CYCLIC GMP; LIPOCALIN; NITRIC OXIDE; TUMOR NECROSIS FACTOR RECEPTOR;

AGE; AGED; ARTICLE; BLOOD LEVEL; BRAIN ISCHEMIA; CELL ACTIVATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HUMAN; HUMAN CELL; LEUKOCYTE ACTIVATION; MAJOR CLINICAL STUDY; MALE; NEUTROPHIL; PRIORITY JOURNAL; RADIOIMMUNOASSAY; STATISTICAL ANALYSIS; STROKE; THROMBOCYTE COUNT;

ACUTE DISEASE; ACUTE-PHASE PROTEINS; ADULT; AGED; AGED, 80 AND OVER; BLOOD PLATELETS; BRAIN ISCHEMIA; CARRIER PROTEINS; CEREBROVASCULAR DISORDERS; CYCLIC AMP; EPOPROSTENOL; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFLAMMATION MEDIATORS; MALE; MIDDLE AGED; NEUTROPHILS; NITRIC OXIDE; ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS; RECEPTORS, TUMOR NECROSIS FACTOR;

EID: 0031754132     PISSN: 10159770     EISSN: None     Source Type: Journal    
DOI: 10.1159/000015873     Document Type: Article

References (55)

1. Prentice RL, Szatrowski TP, Kalo H, Mason MW: Leukocyte counts and cerebrovascular disease.; Chronic Dis 1982;35:703-714.
2. Belch JJF: The relationship between white blood cells and arterial disease. Curr Opin Lipidol 1994;5:440-446.
3. Fisher TC, Meiselmann HJ: Polymorphonuclear leukocytes in ischémie vascular disease. ThrombRes 1994;74(suppl l):21-34.
4. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH: Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997;336: 973-979.
5. Kochanek PM, Hallenbeck JM: Polymorphonuclear leukocytes and monocytes/macrophages in the pathogenesis of cerebral ischemia and stroke. Stroke 1992;23:1367-1379.
6. Aggarwal BB, Kohr WJ, Hass PE, Moffat B, Spencer SA, Henzel WJ, Bringman TS, Nedwin GE, Goeddel DV, Harkins RN: Human tumor necrosis factor: Production, purification and characterization. J Biol Chem 1985;260: 2345-2354.
7. Diez-Ruiz A, Tilz OP, Zangerle R, Baier-Bitterlich G, Wächter H, Fuchs D: Soluble receptors for tumor necrosis factor in clinical laboratory diagnosis. Eur J Haematol 1995;54:l-8.
8. Kjeldsen L, Johnson AH, Sengelov H, Borregaard N: Isolation and primary structure of NGAL, a novel protein associated with human neutrophil gelatinase. J Biol Chem I993;268: 10425-10432.
9. Axelsson L, Bergenfeldt M, Ohlsson K: Studies of the release and turnover of human lipocalin. Scand J Clin Lab Invest 1995;55:577-588.
10. Kelly RA, Smith TW: Cytokines and cardiac contractile function. Circulation 1997;95:778781.
11. Ware J, Heistad DD: Platelet-endothelium interactions. N Engl J Med 1993;328:628-635.
12. Moncada S, Higgs A: The L-arginin-nitric oxide pathway. N Engl J Med 1993;329:20022012.
13. Radomski MW; Palmer RMJ, Moncada S: The role of nitric oxide and cGMP in platelet adhesion to vascular endothelium. Biochem Biophys Res Commun 1987;148:1482-1489.
14. Radomski MW, Palmer RMJ, Moncada S: Endogenous nitric oxide inhibits human platelet adhesion to vascular endothelium. Lancet 1987;ii:1057-1058.
15. Radomski MW, Palmer RMJ, Moncada S: The anti-aggregating properties of vascular endothelium: Interactions between prostacyclin and nitric oxide. Br J Pharmacol 1987;92:639-646.
16. Faraci FM, Brian JE: Nitric oxide and the cerebral circulation. Stroke 1994;25:692-703.
17. Faraci FM, Breese K: Nitric oxide mediator vasodilatation in response to activation of Nmethyl-D-aspartate receptors in brain. Circ Res 1993;72:426-480.
18. Malinski T, Bailey F, Zhang TO, Choop M: Nitric oxide measured by porphyrinic microsensor in rat brain after transient middle cerebral artery occlusion. J Cereb Blood Flow Metab 1993;13:355-358.
19. Sato S, Tominaga T, Ohnishi ST: EPR spintrapping study of nitric oxide formation during bilateral carotid occlusion in the rat. Biochim BiophysActa 1993;! 181:195-197.
20. Tominaga T, Sato S, Ohnishi T, Ohnishi ST: Potentiation of nitric oxide formation following bilateral carotid occlusion and focal cerebral ischemia in the rat: In vivo detection of the nitric oxide radical by electron paramagnetic resonance spin trapping. Brain Res 1993;614: 342-346.
21. Salvemini D, De Nucci G, Gryglewski RJ, Vane JR: Human neutrophils and mononuclear cells inhibit platelet aggregation by releasing a nitric oxide-like factor. Proc Natl Acad SciUSA1989;86:6328-6332.
22. Nicolini FA, Wilson AC, Mehta P, Mehta JL: Comparative platelet inhibitory effects of human neutrophils and lymphocytes. J Lab Clin Med 1990;! 16:147-152.
23. Zatta A, Prodoscimi M, Bertele M, Bazazoni G, Del Maschio A: Inhibition of platelet function by polymorphonuclear leukocytes. J Lab Clin Med 1990;! 16:651-660.
24. Del Maschio A, Evangelista V, Rajtor G, Chen ZM, Cerletti C, De Gaetano G: Platelet activation by polymorphonuclear leukocytes exposed to chemotactic agents. Am J Physiol 1990;258: H870-H879.
25. Libby P, Mitchell RN: Cytokines score a knockout. Harnessing gene targeting to gain insight into the pathogenesis of myocarditis. Circulation 1997;95:551-552.
26. Gross SG, Lev! R: Tetrahydrobiopterin synthesis. J Biol Chem 1992;267:25722-25729.
27. Wiedermann CJ, Beimpold H, Herold M, Knapp E, Braunsteiner H: Increased levels of serum neopterin and decreased production of neutrophil Superoxide anions in chronic heart failure with elevated levels of tumor necrosis factor-alpha. J Am Coll Cardiol 1993;22:18971901.
28. Elneihoum AM, Falke P, Axelsson L, Lundberg E, Lindgärde F, Ohlsson K: Leukocyte activation detected by increased plasma levels of inflammatory mediators in patients with ischémie cerebrovascular diseases. Stroke 1996;27: 1734-1738.
29. Böger RH, Bode-Böger SM, Thiele W, Junker W, Alexander K, Fröhlich JC: Biochemical evidence for impaired nitric oxide synthesis in patients with peripheral arterial occlusive disease. Circulation 1997;95:2068-2074.
30. Panza JA, Quyyumi AA, Brush JE, Epstein SE: Abnormal endothelium-dependent vascular relaxation in patients with essential hypertension. N Engl J Med 1990;323:22-27.
31. Vita JA, Treasure CB, Nabel EG, McLenacham LM, Fish RD, Yeung AC, Vekshtein VI, Selwyn AP, Ganz P: Coronary vasomotor response to acetylcholine relates to risk factors for coronary artery disease. Circulation 1990; 81:491-497.
32. Anderson TJ, Meredith IT, Yeung AC, Frei B, Selwyn AP, Ganz P: The effects of cholesterollowering and antioxidant therapy on endothelium-dependent coronary vasomotion. N Engl JMedl995;332:488-493.
33. Treasure CB, Klein JL, Weintraub WS, Talley JD, Stillabower ME, Kozinski AS, Zhang J, Boccuzzi SJ, Cederholm JC, Alexander RW: Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N Engl J Med 1995;332:481-487.
34. Anwaar I, Gottsäter A, Wallmark A, Hedblad B, Lindgärde F, Mattiasson I: Intraplatelet cyclic 3', S'-guanosine monophosphate is related to serum cholesterol. Int Angiol 1996;15:201206.
35. International Stroke Trial Collaborative Group: The international stroke trial (1ST): A randomised trial of aspirin, subcutaneous heparin, both or neither among 19,435 patients with acute ischaemic stroke. Lancet 1997;349: 1569-1581.
36. CAST Collaborative Group: CAST: Randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. Lancet 1997;349:164I-1649.
37. Van Kooten F, Ciabattoni G, Patrono C, Schimitz P, van Gijn J, Koudstaal P: Evidence for episodic platelet activation in acute ischaemic stroke. Stroke 1994;25:278-281.
38. Ohlsson K, Linder C, Lundberg E, Axelsson L: Release of cytokines and proteases from human peripheral blood mononuclear and polymorphonuclear cells following phagocytosis and LPS stimulation. Scand J Clin Lab Invest 1996;56:461.
39. Brooker G, Harper JF, Terasaki VL, Moylan RD: Radioimmunoassay of cyclic AMP and cyclic GMP; in Brooker G, Greengard P, Robinson GA (eds): Advances in Cyclic Nucleotide Research. New York, Raven Press, 1979, pp 1-32.
40. Gottsäter A, Anwaar I, Hedblad B, Wallmark A, Lindgärde F, Mattiasson I: Higher intraplatelet cyclic nucleotide levels in stroke than in asymptomatic carotid atherosclerosis and controls (abstract). Haemostasis 1996;26(suppl 3): 543.
41. O'Malley T, Langhome P, Elton RA, Stewart C: Platelet size in stroke patients. Stroke 1995; 26:995-999.
42. Elneihoum AM, Falke P, Hedblad B, Lindgärde F, Ohlsson K: Leukocyte activation in atherosclerosis: Correlation with risk factors. Atherosclerosis 1997; 131:79-84.
43. Grau AJ, Sigmund R, Hacke W: Modification of platelet aggregation by leukocytes in acute ischaemic stroke. Stroke 1994;25:2149-2152.
44. Van Dervort AL, Van L, Madara PJ, Cobb JP, Wesley RA, Corriveau CC, Tropea MM, Danner RL: Nitric oxide regulates endotoxin-induced TNF-alpha production by human neutrophils. J Immunol 1994;152:4I02-4109.
45. Nolle C, Eigenthaler M, Schanzenbacher P, Walter U: Endothelial cell-dependent phosphorylation of a platelet protein mediated by cAMP and cGMP-elevating factors. J Biol Chem 1991;266:14808-14812.
46. Polanowska-Grabowska R, Gear AR: Role of cyclic nucleotide in rapid platelet adhesion to collagen. Blood 1994;83:2508-2515.
47. Trovati M, Anfossi G, Massucco P, Mattiello L, Costamagna C, Piretto V, Mularoni E, Cavalot F, Bosia A, Ghigo D: Insulin stimulates nitric oxide synthesis in human platelets and, through nitric oxide, increases platelet concentrations of both guanosine-3',5'-cyclic monophosphate and adenosine-3',5'-cyclic monophosphate. Diabetes 1997;46:742-749.
48. Dennis MS, Bamford JM, Sandercock PAG, Walow CP: A comparison of risk factors and prognosis for transient ischémie attacks and minor strokes. Stroke 1989;20:1494-1499.
49. Ryder REJ, Hayes TM, Mulligan IP, Kingswood JC, Williams S, Owens DR: How soon after myocardial infarction should plasma lipid values be assessed? Br J Med 1984;289:16511653.
50. Chen LAV, Mehta P, Mehta JL: Oxidized LDL decreases L-arginine uptake and nitric oxide synthase protein expression in human platelets. Relevance of the effect of oxidized LDL on platelet function. Circulation 1996;93:17401746.
51. Karpatkin S: Heterogeneity of human platelets. VI. Correlation of platelet function with platelet volume. Blood 1978;51:307-316.
52. Hoffmann G, Göbel BO, Harbrecht U, Vetter H, Düsing R: Platelet cAMP and cGMP in essential hypertension. Am J Hypertens 1992; 5:847-850.
53. Watanabe H, Kakihana M, Ohtsuka S, Enomoto T, Ysui K, Sugishita Y: Platelet cGMP. A potentially useful indicator to evaluate the effects of nitroglycerine and nitrate tolerance. Circulation 1993;88:29-36.
54. Epstein F, Vane J, Anggard E, Bolting R: Regulatory function of the vasodilatory endothelium. N EngI J Med 1990;323:27-36.
55. Toktmaga O, Yamada T, Fan JL, Watanabe T: Age related decline in prostacyclin synthesis by human aortic endothelial cells. Qualitative and quantitative analysis. Am J Pathol 199I;138: 941-949.